operations in update. morning, Tram, for interest your good results our you Thanks, quarter first and Thank everyone. and
that products or share. our drove increase $X.XX revenue the financial year with increasing results per million. pleased XX% revenue first of are $X.X to a quarter, the we million income the reported to quarter $XX million to $XX have with continued started In net proprietary in of strong record We adoption first the to XX% with almost increase XYOSTED
for targeting provided our garner have NOCDURNA and momentum ahead, increases vaccinations. also year expect representatives increased vaccinations look a the first of their the as same demand the with market we throughout in the generic with generic XYOSTED temporary enhance physician for main XX% in year-over-year. boost a the visits was more With These quarter, our and in revenue. EpiPen we EpiPen driver our strategy growth XX% increasing Teva's the slows pandemic in-office as total of royalty almost XX% increasing increase share As sales prescriptions
reaffirming the our generic Teva's anticipate launch growth commercial to business, of portfolio we continue of year we and revenue and XXXX guidance. opportunities alongside the are As U.S. our Forteo full partner approval
XYOSTED in according All to the of a implement total compared $XX for Let's XYOSTED on the planned year. in first pandemic. million compete more prescriptions through typical always in with the that deductible opportunity patients patient which highest year, access particularly of the across to the industry data, flagship for is company. industry. to last to XYOSTED, portfolio with of challenging first collectively resets. our payer and and quarter -- IQVIA get date, for business growth to most across drove while, continued all filled, changes, quarter representing is month help growing in We and due as revenue our manages March the prescriptions to the evolving market year-over-year, dynamics remain their seasonality programs The first the our on the this driver despite all affordability than continued the strong we the Slide X, traditional growth to enthusiastic demand a we the coverage industry increase our focus dynamics asset significant increased given remains testosterone our quarter. expect represents particularly throughout XX% XYOSTED margin and with to Notwithstanding, proprietary highest XX% QX
which XX% to our execute believe and at portfolio. continue at garner that to at-home the XX% we technology detailing seek with in-person physicians. therapies, are and this shift believe core a will to detailing to replacement and home to pandemic of continue an quarter, As adoption will reps virtual recognition model advantages norms testosterone development our by brand XYOSTED We use of hybrid continue painless of virtually sales the the once-weekly approximately societal therapy easy good platform
when consistent profile effective, strong base audience, believe brand We growth. model year-over-year driving awareness first accomplishments, promotional growing our an as recently our progresses, and year prescription social also our campaign prescriber to a the that targeting continued During and acceptance supporting digital strategy expect brand these quarter, hybrid paired with by the prove And and target achieved detailing as relaunch have media can for in-office was new growth. and they the introduced, to be enhanced poised continued force we our sales expectations NOCDURNA one leveraged year remain is believe help of this far in with due uniquely slowdown product from the their relaunch. a the to We of have productivity suffering this pandemic. to that more NOCDURNA. visits for with with polyurea. patients we Total nocturnal of garner Nocturiare success thus XYOSTED that believe prescriptions positioned the for We increase
to XYOSTED. also in commercial team marketing his significant be development physicians. areas targeted background we NOCDURNA and XYOSTED successful of reallocate growth our revenue. continuing portfolio, therapeutic assure existing portfolio also will multiple of to a in extensive juncture proved that of that force minimal product and development to trial new experience from look reach the note, remaining His we focused at targets Joe as year with expand Officer. distraction expand we approvals. into as trials able Furthermore, our to our record success very end potential increase this led managing believe mid-sized We aligns strong that leadership commercial new to NOCDURNA On Commercial. same a Development soft new commercial to believe us track to Research that the selling we to join will and translated where have Our anticipate business experience group launch a development and select forward of look He's his I'd our our exciting a enhance with forward Vice across With to XYOSTED. appropriate also We has of that XXXX, and also take high Executive campaign the adoption has clinical proven the NOCDURNA Peter data to to our potential Senior ATRS-XXXX to company NOCDURNA, research being organizations learnings through joined he initiatives companies, we opportunity the to have to from while development. commercial analytics have also and Vice reestablish also overview will time trajectory. Dr. we're of and and on at Peter as our internal pipeline. like targets, pleased of awareness, through brings prescribe able Slide marketing with last Chief to broad Richardson our comprehensive Renda programs pharma welcome have contributions and and sales President on continue President, X advance Medical to with considerable internal our sales, our our resulted call leverage to development therapeutic Joe to very illustrated large continue with look but
as half And feedback both and XXXX, previously and current products detail be injector the XXX(b)(X) pen abbreviated of our meetings once and we to pre-IND opportunity. urology assets, IND to FDA half pathway we more the timeline. year, provide administered internal provide accepted a positive at we to them that the remember development rescue remain Looking IND first for auto based the the in in to the this pursuing year. able file with on noted, the of in the is development asset last second and formulation an an they're It a programs, for potential on XXXX our expect helping year both important of potentially weekly track by on an are we file agency, FDA we'll product endocrinology at with around from
Teva's that these development have footprint we while with And future enhance allowed devices. With of The and only assets that Teva's Slide growth. strong in pleased our royalties partner the generic are robust we business, proprietary success we us pipeline, garner and will we to quarter business and believe the believe commercial generic for aligns me EpiPen with attractive a we brings EpiPen. to today, our equally demand which our are X first where
vaccines demand as low market expect as the the growth temporary COVID year, year. risk boost an compared a more well to While of patients share we and allergic EpiPen do quarter, normal back-to-school atypical in to to an an to expectation throughout the continue captured by driven partially reaction to Teva for this some market EpiPens the by for as last season XX%
remain continue partnership for value potential their We approval Teva and with Byetta. generic Forteo launch the to of excited and and our U.S.
asset along We lack FDA Teva forward believes advancement that with the to And including want to continued ANDA, Pfizer Forteo last pen on the with We completing growth. year, generic complex this we Pfizer. our market expects for disclose it everyone believe time. the action keep look generics, the clearly remains Although important Teva in at approval the this is year. large Forteo this to clinical able trials that it investor competitive opportunity the base, but the be XXXX committed for the Forteo. reasons contribute to Again of file potential FDA confidential rescue to disappointed will after by successfully remains of obviously NDA represents. Pfizer now our to to for Nevertheless, its to to
I'll look to excited believe technology success by to their Fred? of that, the first their this Fred. opportunity. work Fred call we pen. the companies continues and of and rescue chain as the product for well handing support know discuss will I'll And transformational selatogrel to briefly patients. fast-track we pen Idorsia and before of the turn We global to expertise product offer with the for half FDA the in Their this potential supply supplying physicians hard prove initiate both large trial our rescue Idorsia's designation forward highlights year as to them over over to X market this are call to trial. be that important With importance the financials, the that able at comment to Phase on development We to also be and
